OncoDaily Pulse

Aug 29, 2025, 22:06

Wenxin (Vincent) Xu: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register via the link.

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Wenxin (Vincent) Xu

Dr. Wenxin (Vincent) Xu is an Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at Dana-Farber Cancer Institute in Boston. He specializes in the management of kidney cancer with a focus on perioperative care and risk assessment for localized disease.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Xu will present on “Management of Post-Surgical Recurrence”. His presentation will explore:

Strategies for risk assessment following surgical treatment of renal cell carcinoma.
Approaches to monitoring and early intervention for post-surgical recurrence.
The latest advances in perioperative management aimed at reducing recurrence risk.
Integrating multidisciplinary care to optimize patient outcomes after surgery.

With a strong foundation in both clinical practice and research, Dr. Xu emphasizes personalized management plans that address recurrence risks while enhancing long-term survival and quality of life for patients with localized RCC.

Global Voices in Renal Oncology (VIRO) 2025

cancer Dana-Farber Cancer Institute Global Voices in Renal Oncology Harvard Medical School kidney cancer OncoDaily Oncology RCC renal cell carcinoma VIRO 2025 Wenxin (Vincent) Xu

Why Is Financial Wellness Crucial for Physicians and Health Care Professionals?

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

10 Leading Experts Join OncoDaily Medical Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation

Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control